Jagsonpal Pharmaceuticals LimitedQuarter ended 30 September 2026 Results & Financial Update
Jagsonpal Pharmaceuticals Limited: Quarter ended 30 September 2026 consolidated results and company financials – revenue ₹96.37 Cr, PAT ₹12.29 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Jagsonpal Pharmaceuticals price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Jagsonpal Pharmaceuticals Quarter ended 30 September 2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
During the second quarter of fiscal 2027, Jagsonpal Pharmaceuticals reported consolidated revenue from operations of INR 96.371 crore, representing a 29% increase over the previous year driven by organic momentum and the integration of Aequitas Healthcare. On a standalone basis, revenue grew by 9.3% YoY to INR 81.4 crore.
Profit after tax (PAT) for the consolidated entity stood at INR 12.287 crore, with total income reaching INR 98.627 crore and profit before tax (PBT) recorded at INR 16.419 crore. Basic and diluted earnings per share (EPS) for the quarter were INR 1.86.
The quarter was characterized by deliberate upfront investments in growth drivers, including the expansion of the hospital sales team, the appointment of a new business head at Aequitas Healthcare, and foundational marketing planning for the wellness portfolio of Group Pharma. These calibrated investments held EBITDA flat on a standalone basis at a 22.7% margin, with management anticipating the benefits to flow into profitability from the third quarter onwards.
Inorganic expansion played a pivotal role during the period. Aequitas Healthcare, in which the company acquired an 85% stake for an all-cash consideration of INR 20.8 crore (INR 208 million), was consolidated starting from the second quarter. This acquisition opened up the institutional hospital channel with access to over 1,000 hospitals.
Subsequent to the quarter close, on October 1, 2026, the company completed the acquisition of the wellness portfolio from Group Pharma via a Business Transfer Agreement, further strengthening its presence in the wellness and OTC segment across India.
The company maintained a robust financial position, holding a cash and cash equivalents balance of INR 134.7 crore (INR 1,347 million) as of September 30, 2026, even after funding the Aequitas stake acquisition and executing an enhanced dividend payout of 200% in September 2026.
01 · Business model
What does Jagsonpal Pharmaceuticals do?
Jagsonpal Pharmaceuticals Limited is a 100% India-centric, asset-light branded-generics pharmaceutical company operating with a legacy dating back to 1964. The company specializes in sub-chronic therapies spanning gynaecology, orthopaedics, dermatology, wellness, and critical care.
The company's operating model relies on an asset-light framework where capital-intensive manufacturing and research activities are outsourced to contract manufacturing organizations (CMOs) that comply with WHO-GMP and ISO 9001:2015 standards, allowing the company to focus on product ideation, brand management, and widespread distribution.
Jagsonpal reaches over 137,000 doctors and 1,000 hospitals nationwide, distributing its products through a network of 18 stocking points and approximately 3,500 stockists, supported by a field force of over 1,100 medical representatives.
02 · Historical context
What shaped the business before this quarter
Between FY22 and FY26, the company expanded its annual revenue from INR 2,176 million to INR 2,872 million at a CAGR of 7.2%, while growing operational PAT 2.4x and improving free cash flow conversion from 52% to 92%.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Quarter ended 30 September 2026 |
|---|---|
| Revenue from operations | ₹96.37 Cr |
| Total income | ₹98.63 Cr |
| Profit before tax | ₹16.42 Cr |
| Profit after tax | ₹12.29 Cr |
| EPS | ₹1.86 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Standalone revenue grew by 9.3% YoY to INR 81.4 crore, supported by a 10% increase in medical representative (MR) productivity and strong performance from top power brands such as Maintane Inj. (up 33.7% in brand MAT) and Maintane Tab (up 67.7%).
Consolidated revenue rose to INR 96.371 crore, reflecting a 29% total top-line expansion aided by the inclusion of Aequitas Healthcare from Q2 FY27.
What drove margins
Standalone gross margin expanded by 70 basis points YoY during the quarter, with contribution higher by 10.5%, supported by favorable product mix and realization.
Standalone EBITDA margin stood at 22.7% (pre-ESOP), reflecting a 151 basis point YoY change due to deliberate upfront investments in an expanded hospital team, leadership additions at Aequitas, and marketing preparations for the Group Pharma wellness portfolio.
05 · Demand, customers & order book
Where demand is coming from
The company engages over 1,37,000 doctors across India and covers more than 1,000 hospitals following the integration of Aequitas Healthcare's institutional channel.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company maintains strong leadership positions, ranking #7 in gynaecology (engaging 35,000 of 39,000 gynaecologists) and #2 in orthopaedics (engaging 10,000 of 13,000 orthopaedicians) according to corporate CVM metrics.
Therapy breadth expanded beyond gynaecology, orthopaedics, and dermatology with the addition of critical care and the wellness portfolio from Group Pharma.
Geography and market mix
Products are distributed across more than 4,000 towns and cities via 18 stocking points, reaching over 50,000 doctors nationwide.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Manufacturing remains entirely outsourced to leading contract manufacturing organizations (CMOs) that comply with WHO-GMP and ISO 9001:2015 standards, maintaining over 300 quality checks without capital expenditure on production plants.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The acquisition of an 85% stake in Aequitas Healthcare for INR 20.8 crore (all-cash) was consolidated in Q2 FY27, bringing access to 1,000+ hospitals and initiating supply chain streamlining, cost rationalization, and cross-selling of JPL brands.
Completed the acquisition of Group Pharma's wellness portfolio on October 1, 2026, integrating it within the largest division with field force inductions and training completed to drive volume growth from Q3 onwards.
09 · Reported developments
What changed operationally
Medical representative productivity increased by 10%, driving strong organic performance where 7 out of the company's top 10 brands outperformed their respective markets.
10 · Items worth noticing
The line items that can distort a quick read
Standalone financials record an exceptional item of INR 2 million (INR 20 lakh) in Q2 FY27 representing transaction and integration costs relating to the Aequitas acquisition.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Standalone cash and cash equivalents stood at INR 1,347 million (INR 134.7 crore) as of September 30, 2026, after accounting for the INR 20.8 crore Aequitas acquisition and an enhanced dividend payout of 200% (INR 264 million) disbursed in September.
Standalone net working capital was reported at INR 151 million as of September 30, 2026, compared to INR 120 million as of June 30, 2026.
Capital allocation & funding
Both Jagsonpal standalone and acquired entities maintain a debt-free capital structure with nil borrowings.
12 · Management guidance & targets
What management is targeting from here
Management expects quarterly revenues to cross INR 1,000 million in Q3 FY27 and remains on track to achieve 'Mission 2028' of reaching INR 5,000 million in annual revenue through organic growth and accretive acquisitions.
13 · Beyond the numbers
What changed beyond the numbers
Reported update
MySakhi CSR Initiative
The company's MySakhi platform advanced community health and sanitation efforts by establishing 20 functional pink toilet blocks, benefiting 10,772 girl students, and conducting 24 specialist-led webinars on women's health.
14 · Previous-quarter changes
What changed since the previous quarter
Standalone cash and cash equivalents changed from INR 1,700 million as of June 30, 2026, to INR 1,347 million as of September 30, 2026, primarily reflecting outflows for the Aequitas acquisition and the 200% dividend payout.
15 · Key Q&A
The quarter, answered directly
What does Jagsonpal Pharmaceuticals do?
Jagsonpal Pharmaceuticals Limited is a 100% India-centric, asset-light branded-generics pharmaceutical company operating with a legacy dating back to 1964. The company specializes in sub-chronic therapies spanning gynaecology, orthopaedics, dermatology, wellness, and critical care.
What is the clearest takeaway from Quarter ended 30 September 2026?
During the second quarter of fiscal 2027, Jagsonpal Pharmaceuticals reported consolidated revenue from operations of INR 96.371 crore, representing a 29% increase over the previous year driven by organic momentum and the integration of Aequitas Healthcare. On a standalone basis, revenue grew by 9.3% YoY to INR 81.4 crore.
What drove revenue or demand?
Standalone revenue grew by 9.3% YoY to INR 81.4 crore, supported by a 10% increase in medical representative (MR) productivity and strong performance from top power brands such as Maintane Inj. (up 33.7% in brand MAT) and Maintane Tab (up 67.7%).
What mattered most for margins or profitability?
Standalone gross margin expanded by 70 basis points YoY during the quarter, with contribution higher by 10.5%, supported by favorable product mix and realization.
What changed operationally beyond the headline numbers?
Manufacturing remains entirely outsourced to leading contract manufacturing organizations (CMOs) that comply with WHO-GMP and ISO 9001:2015 standards, maintaining over 300 quality checks without capital expenditure on production plants.
What is management guiding or targeting from here?
Management expects quarterly revenues to cross INR 1,000 million in Q3 FY27 and remains on track to achieve 'Mission 2028' of reaching INR 5,000 million in annual revenue through organic growth and accretive acquisitions.
16 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
17 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Q3 FY27 Revenue Milestone: Monitor whether consolidated quarterly revenue successfully crosses the INR 1,000 million threshold in Q3 FY27 as guided by management.
- 02
Synergy Realization from Acquisitions: Track the financial contribution and margin impact of the newly integrated Group Pharma wellness portfolio and the Aequitas hospital channel integration starting in Q3 and Q4 FY27.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.